Ligand Raises Fourth Quarter and Full Year 2013 Financial Forecast
Ligand Announces Highlights from Today’s Analyst Day Event
Ligand Initiates Phase 1 Trial with Glucagon Receptor Antagonist for Type 2 Diabetes
Reminder: Ligand to Host Analyst Day on November 14th in Chicago
Ligand Reports Third Quarter Financial Results
Ligand to Host Analyst Day on November 14th in Chicago
Ligand to Report Third Quarter Results on October 30th
Ligand Announces FDA Acceptance of Investigational New Drug Application for Glucagon Receptor Antagonist Program
Ligand Partner GSK Receives Marketing Authorization from the European Commission for Additional Revolade™ (Eltrombopag) Indication as the First Approved Treatment for Chronic Hepatitis C-Associated Thrombocytopenia
Ligand Enters Global License Agreement with CURx Pharmaceuticals, Inc. for Captisol-EnabledTM Topiramate Injection
Ligand Reports Second Quarter Financial Results
Ligand Partner GlaxoSmithKline Receives Positive CHMP Opinion for REVOLADE™ in Thrombocytopenia Associated with Chronic Hepatitis C Infection
Ligand Receives Orphan Designation for Captisol-EnabledTM Topiramate Injection
Ligand Signs License Agreement with Ethicor for Oral Lasofoxifene
